Steve please do find it (Phase III trials of Viagra) if possible. Although I think that head-to-head comparison of Viagra vs. Muse is irrelevant to the stock movement today. Remember we are talking about a multi-billion dollar market, I don't think that the issue will be decided by double blind studies.
Below is the only Published abstract in English on Medline about Viagra (Sindelafil) that I can find along with two other references. If someone has the letter from the Brit J Urol, that might have some other useful references. Right now I would prefer that Viagra was out on the market. A drug that has not been approved, with no large studies published, has no cost, no risk, and is a miracle that works on everyone. It has no flaws, like your wife's first husband. <g>
BTW the excerpt from Slaughterhouse Five was from a book that was written by Kilgore Trout and found in the window of a porno shop by the protaganist Billy Pilgram who, "...had a tremendous wang, incidentally. You never know who'll get one."
------------------------------------------------
ncbi.nlm.nih.gov
Sildenafil, a novel effective oral therapy for male erectile dysfunction.
Boolell M, Gepi-Attee S, Gingell JC, Allen MJ
Department of Urology, Southmead Hospital, Westbury on Trym, Bristol, UK.
OBJECTIVES: To determine the efficacy and safety of sildenafil, a novel orally active inhibitor of the type-V cyclic guanosine monophosphate-specific phosphodiesterase (the predominant isoenzyme in the human corpus cavernosum) on penile erectile activity in patients with male erectile dysfunction of no established organic cause. PATIENTS AND METHODS: Twelve patients (aged 36-63 years) with male erectile dysfunction of no established organic cause were entered into a double-blind, randomized, placebo-controlled, crossover study which was conducted in two phases. In the first phase (four-way crossover), treatment efficacy was evaluated by measurements of penile rigidity using penile plethysmography during visual sexual stimulation at different doses of sildenafil (10, 25 and 50 mg or placebo). In the second phase (two-way crossover), efficacy was assessed by a diary record of penile erectile activity after single daily doses of sildenafil (25 mg) or placebo for 7 days. RESULTS: The mean (95% confidence interval, CI) duration of rigidity of > 80% at the base of the penis was 1.3 min (0.4-3.1) in patients on placebo, 3.5 min (1.6-7.3; P = 0.009) on 10 mg, 8.0 min (3.7-16.7; P = 0.003) on 25 mg and 11.2 min (5.6-22.3; P < 0.001) on 50 mg of sildenafil. The mean (95% CI) duration of rigidity of > 80% at the tip of the penis was 1.2 min (0.4-2.7) on placebo and 7.4 min (2.4-8.5; P = 0.001) on 50 mg sildenafil. From the diary record of daily erectile activity, the mean (95% CI) total number of erections was significantly higher in patients receiving sildenafil was 6.1 (3.2-11.4), compared with 1.3 (0.5-2.7) in those on placebo; 10 of 12 patients reported improved erectile activity while receiving sildenafil, compared with two of 12 on placebo (P = 0.018). Six patients on active treatment and five on placebo reported mild and transient adverse events which included headache, dyspepsia and pelvic musculo-skeletal pain. CONCLUSION: These results show that sildenafil is a well tolerated and effective oral therapy for male erectile dysfunction with no established organic cause and may represent a new class of peripherally acting drug for the treatment of this condition.
MeSH Terms:
3',5'-Cyclic-GMP Phosphodiesterase/antagonists & inhibitors*
Administration, Oral
Adult
Dose-Response Relationship, Drug
Double-Blind Method
Human
Impotence/drug therapy*
Male
Middle Age
Patient Satisfaction
Penile Erection/drug effects*
Piperazines/administration & dosage*
Plethysmography
Time Factors
Treatment Outcome
Substances:
sildenafil
Piperazines
3',5'-Cyclic-GMP Phosphodiesterase
PMID: 8813924, MUID: 96408939
-----------------------------------------------
ncbi.nlm.nih.gov
Br J Urol 1997 Apr;79(4):663-664
Sildenafil: a novel effective oral therapy for male erectile dysfunction.
[LETTER]
Mulhall J
-------------------------------------------------------
ncbi.nlm.nih.gov
Prog Urol 1997 Feb;7(1):108-109
Treatment per os of disorders of erection.
[Article in French]
Giuliano F
------------------------------------------------------
By the way, National Library of Medicine searches are now free to the public. The search engine PUBMED is more user friendly than GREATFUL MED (apologies to Jerry Garcia RIP). The URL is nlm.nih.gov
Zebra |
